Article info

Download PDFPDF
Original article
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention
  1. Correspondence to Jurrien M ten Berg, Department of Cardiology, St Antonius Hospital, P O Box 2500, 3435 CM Nieuwegein, The Netherlands; j.ten.berg{at}antoniusziekenhuis.nl
View Full Text

Citation

Breet NJ, van Werkum JW, Bouman HJ, et al
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention

Publication history

  • Accepted February 22, 2011
  • First published April 8, 2011.
Online issue publication 
May 16, 2011

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.